摘要
抗血管内皮生长因子(VEGF)药物的出现及其在视网膜领域的应用,是视网膜疾病的一次革命性举措。一些过去无法治疗或疗效不佳的视网膜疾病,如年龄相关性黄斑变性(AMD)、糖尿病视网膜病变(DR)、视网膜静脉阻塞(RVO)等,在应用抗VEGF药物后使绝大多数患者保存了视力,约1/3病例视力甚至提高。本文叙述视网膜疾病中,根据循证医学及文献复习,提出哪些应是首选使用,哪些可以考虑使用,哪些则是无效的,并简单介绍它们的用法及并发症。
The advent of anti-vascular endothelial growth factor (VEGF)and its administration in retinal vascular diseases such as age-related macular degeneration (AMD) , diabetic retinopathy and retinal vein occlusion etc. are revolutionary events. Those previously considered untreatable diseases, now become manageable with intravitreal injection of anti-VEGF. Clinical results showed not only visual acuity can be preserved in most of the patients, even vision gained in about 1/3 of the cases after treatments. Based on evidence-based medicine as well as literature review, this article described the diseases which will be most benefit from anti-VEGF therapy, and the diseases that may be effective and the diseases probably are ineffective. In addition, the interval of drag application and its adverse side effects were briefly discussed.
出处
《中国眼耳鼻喉科杂志》
2018年第1期2-6,共5页
Chinese Journal of Ophthalmology and Otorhinolaryngology
关键词
抗血管内皮生长因子
年龄相关性黄斑变性
糖尿病视网膜病变
视网膜静脉阻塞
循证医学
Anti-vascular endothelial growth factor
Age-related macular degeneration
Diabetic retinopathy
Retinal vein occlusion
Evidence-based medicine